Analyst Activity – Wedbush Reiterates Outperform on Fate Therapeutics (NASDAQ:FATE)

ME Staff
-
0

Analyst Ratings For Fate Therapeutics (NASDAQ:FATE)

Today, Wedbush reiterated its Outperform rating on Fate Therapeutics (NASDAQ:FATE) with a price target of $10.00.

Some recent analyst ratings include

  • 3/6/2018-Wedbush Reiterated Rating of Outperform .
  • 3/6/2018-HC Wainwright was Downgraded by analysts at HC Wainwright from a “Buy ” rating to a ” Neutral” rating. They now have a $12.00 price target on the stock.
  • 3/6/2018-Wells Fargo & Co Reiterated Rating of Outperform.
  • 3/6/2018-Piper Jaffray Companies Reiterated Rating of Overweight .
  • 12/12/2017-Raymond James Financial Reiterated Rating of Buy.
  • 9/8/2017-Leerink Swann Reiterated Rating of Outperform .

Recent Insider Trading Activity For Fate Therapeutics (NASDAQ:FATE)
Fate Therapeutics (NASDAQ:FATE) has insider ownership of 10.88% and institutional ownership of 68.75%.

  • On 10/16/2017 Cindy Tahl, General Counsel, sold 8,091 with an average share price of $3.85 per share and the total transaction amounting to $31,150.35.
  • On 10/16/2017 Daniel D Shoemaker, Insider, sold 13,225 with an average share price of $3.87 per share and the total transaction amounting to $51,180.75.
  • On 11/23/2016 Chris Storgard, Insider, bought 37,593 with an average share price of $2.66 per share and the total transaction amounting to $99,997.38.
  • On 11/23/2016 William H Rastetter, Director, bought 375,939 with an average share price of $2.66 per share and the total transaction amounting to $999,997.74.
  • On 6/12/2014 Peter D Flynn, Insider, sold 6,488 with an average share price of $7.00 per share and the total transaction amounting to $45,416.00.
  • On 6/10/2014 Peter D Flynn, Insider, sold 3,305 with an average share price of $7.00 per share and the total transaction amounting to $23,135.00.
  • On 5/1/2014 Peter D Flynn, Insider, sold 9,793 with an average share price of $7.07 per share and the total transaction amounting to $69,236.51.

Recent Trading Activity for Fate Therapeutics (NASDAQ:FATE)
Shares of Fate Therapeutics closed the previous trading session at with shares trading hands.